All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Completed, but no date, and reported results | 2004-002102-30 | OPEN-LABEL, SINGLE-ARM STUDY OF THE SAFETY AND EFFICACY OF CC-5013 MONOTHERAPY FOR SUBJECTS WITH MULTIPLE MYELOMA A COMPANION STUDY FOR STUDIES THAL-MM-003, CC-5013-MM-009, AND CC-5013-MM-010 | bad-data | |
| Reported results | 2005-000454-73 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH... | 2014-06-24 | due-trials |
| Reported results | 2005-004937-16 | Randomised, Controlled, Open-Label, Multi-Centre Comparison of Thalidomide Versus High-Dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma | 2009-01-05 | due-trials |
| Reported results | 2006-000057-22 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Comparison Study of CC-10004 in Subjects with Moderate-to-severe Plaque-Type Psoriasis | 2007-02-07 | due-trials |
| Reported results | 2006-001865-41 | A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Pre... | 2016-04-13 | due-trials |
| Reported results | 2006-001956-11 | Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLC | 2010-09-07 | due-trials |
| Reported results | 2006-002517-12 | A multicenter, single-arm, open-label expanded access study of lenalidomide plus dexamethasone in previously treated subjects with relapsed/refractory Multiple Myeloma. | 2009-11-13 | due-trials |
| Reported results | 2006-004469-32 | A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF TWO LENALIDOMIDE DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA | 2010-02-25 | due-trials |
| Reported results | 2006-004500-40 | A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN’S LYMP... | 2011-04-27 | due-trials |
| Reported results | 2006-004532-73 | A MULTICENTER, SINGLE-ARM, OPEN-LABEL EXPANDED ACCESS PROGRAM FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED SUBJECTS WITH MULTIPLE MYELOMA | 2010-03-12 | due-trials |
| Reported results | 2006-004553-17 | A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT OR I... | 2013-09-24 | due-trials |
| Reported results | 2006-004619-23 | A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two dose regimens of CC-10004 in subjects with active psoriatic arthritis | 2009-05-08 | due-trials |
| Reported results | 2006-004785-14 | A Phase II Trial of Single-Agent Amrubicin in Patients with Extensive Disease Small Cell Lung Cancer that is Refractory or Progressive within 90 Days of Completion of First-Line Platinum-based Chemoth... | 2009-01-31 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-001626-27 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL CHRONIC... | 2020-11-09 | bad-data |
| Reported results | 2007-002171-13 | A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY T-CELL NON-HODGKIN’S LYMPHOMA | 2010-04-06 | due-trials |
| Reported results | 2007-003989-18 | A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of ... | 2011-05-23 | due-trials |
| Reported results | 2007-004097-32 | An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma | 2014-01-31 | due-trials |
| Reported results | 2007-004823-39 | A PHASE III, RANDOMIZED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK CY... | 2016-07-14 | due-trials |
| Reported results Terminated | 2007-005670-31 | A phase 2, multicenter, open-label, single arm, two-stage study to evaluate the efficacy and safety of CC-4047 (Pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are re... | 2008-09-17 | due-trials |
| Reported results | 2007-007756-34 | A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID) IN PATIENTS WITH MANTLE CELL NHL WHO HAVE RELAPSED OR PROGRESSED AFTER... | 2018-01-08 | due-trials |
| Reported results | 2008-003079-32 | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) VERSUS CHLORAMBUCIL AS FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PA... | 2018-09-05 | due-trials |
| Reported results | 2008-003389-25 | A PHASE 2, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY TO DETERMINE THE EFFICACY OF LENALIDOMIDE (REVLIMID) VERSUS INVESTIGATORS CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA | 2018-10-09 | due-trials |
| Reported results | 2008-006177-32 | A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID) IN PATIENTS WITH MANTLE-CELL LYMPHOMA | 2011-03-02 | due-trials |
| Reported results | 2008-007969-23 | A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER | 2016-11-28 | due-trials |
| Reported results | 2009-009836-54 | A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY OF THE SAFETY AND EFFICACY OF DIFFERENT LENALIDOMIDE (REVLIMID®) DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CH... | 2017-09-05 | due-trials |
| Reported results | 2009-011305-17 | A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas | 2013-04-01 | due-trials |
| Reported results | 2009-011513-24 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS PLACEBO IN SUBJECTS WITH TRANSFUSION-DE... | 2018-05-09 | due-trials |
| Reported results | 2009-012346-23 | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, STUDY OF AZACITIDINE (VIDAZA®)VERSUS CONVENTIONAL CARE REGIMENS FOR THE TREATMENT OF OLDER SUBJECTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA | 2016-07-25 | due-trials |
| Reported results | 2009-012665-61 | A PHASE 2, OPEN-LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH CETUXIMAB IN PRETREATED SUBJECTS WITH KRAS MUTANT METASTATIC COLORECTAL CANCER | 2011-01-25 | due-trials |
| Reported results | 2009-013483-38 | A PHASE 2/3 MULTICENTER, RANDOMIZED OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS INVESTIGATOR?S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B... | 2018-04-05 | due-trials |
| Reported results | 2010-018385-23 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis | 2017-01-13 | due-trials |
| Reported results | 2010-018386-32 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | 2017-01-27 | due-trials |
| Reported results | 2010-018965-42 | A PHASE-3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE EFFICACY AND SAFETY OF POMALIDOMIDE IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM -ASSOCIATED MYEL... | 2018-05-15 | due-trials |
| Reported results | 2010-019820-30 | A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone versus High-Dose Dexamethasone in Subjects with Ref... | 2017-08-29 | due-trials |
| Reported results Terminated | 2010-019926-15 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO COMPARE THE EFFICACY AND SAFETY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE RHEUMATOID ... | 2012-09-10 | due-trials |
| Reported results | 2010-019941-24 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis and a... | 2017-02-09 | due-trials |
| Reported results | 2010-019991-55 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS Studio di fase 3, m... | 2016-11-30 | due-trials |
| Reported results | 2010-019992-30 | A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis Studio di fase 3, mult... | 2016-11-30 | due-trials |
| Reported results | 2010-020324-22 | A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who h... | 2017-08-16 | due-trials |
| Reported results | 2010-023040-32 | A phase IV, Open-Label, Single-Arm ROLLOVER STUDY FOR SUBJECTS WHO PARTICIPATED IN OTHER ROMIDEPSIN PROTOCOLS. Estudio de extensión de fase IV, abierto, de un solo brazo para pacientes que hayan part... | 2013-02-28 | due-trials |
| Reported results | 2010-023047-15 | A Phase 2 Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-40... | 2016-11-03 | due-trials |
| Reported results | 2010-023343-16 | Open-label, multi-center, single-arm study for the safety and efficacy of Pomalidomide (CC-4047) monotherapy for subjects with refractory or relapsed and refractory multiple myeloma: a companion study... | 2014-07-31 | due-trials |
| Reported results | 2011-001555-37 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) in the treatment of active ankylosing spondyliti... | 2018-10-25 | due-trials |
| Reported results | 2011-004558-24 | A PHASE 1A/1B, MULTICENTER, OPEN LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE DUAL DNA-PK AND TOR KINASE INHIBITOR, CC-115, ADMINISTER... | 2021-03-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-005659-15 | A Phase 2a, open-label, dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta (β)- thalassemia | 2022-05-24 | bad-data |
| Reported results | 2012-000859-14 | A phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, In Subjects with Moderate to Se... | 2016-04-04 | due-trials |
| Reported results | 2012-001888-78 | A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA STUDIO MULTICENTRI... | 2019-12-11 | due-trials |
| Listed as ongoing, but also has a completion date | 2012-002471-34 | A Phase 3, Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red ... | 2023-12-23 | bad-data |
| Reported results | 2012-002601-22 | AN OPEN-LABEL, RANDOMIZED, PHASE 2, PARALLEL, DOSE-RANGING, MULTICENTER STUDY OF SOTATERCEPT FOR THE TREATMENT OF PATIENTS WITH ANEMIA AND LOW- OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES OR NON-... | 2018-04-30 | due-trials |
| Reported results | 2012-002714-40 | A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF... | 2017-04-13 | due-trials |
| Reported results | 2012-003123-38 | A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY TO... | 2019-08-30 | due-trials |
| Ongoing | 2012-003457-28 | A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subje... | not-yet-due | |
| Reported results | 2012-003788-23 | A Phase 2 Multicenter, Randomized, Open Label, Multiple Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects with End-Stage Kidney Disease on Hemodialysis Swi... | 2016-08-23 | due-trials |
| Exempt, with results | 2012-005805-36 | A Phase 1/2, Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects with Acute Myeloid Leukemia or Mye... | 2017-05-18 | not-yet-due |
| Reported results | 2013-000113-20 | A PHASE 2/3, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF WEEKLY nab®-PACLITAXEL IN COMBINATION WITH GEMCITABINE OR CARBOPLATIN, COMPARED TO GEMCITABINE/CARBOPLATIN, AS FIRST LINE TREATMENT IN SUBJEC... | 2016-10-28 | due-trials |
| Trial is partly outside EEC, and reported results | 2013-000144-26 | A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid ... | 2018-11-06 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2013-001245-14 | A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lympho... | 2022-01-26 | bad-data |
| Reported results | 2013-001590-25 | A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) MONOTHERAPY IN SUBJECTS WITH ACTIVE PSORIATIC A... | 2016-11-17 | due-trials |
| Reported results | 2013-001729-26 | Phase 3b, Randomized Trial of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® (Bortezomib) Induction Therapy in Newly Diagnosed Multiple Myeloma | 2020-10-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-001903-36 | A PHASE 2 MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF POMALIDOMIDE (CC-4047) IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELO... | 2021-07-28 | bad-data |
| Completed, but no date, and reported results Terminated | 2013-002291-41 | A Randomized, Open Label, Multi-Center Phase 2 Study of nab-Paclitaxel versus Epigenetic Modifying Therapy of CC-486 with nab-Paclitaxel in Subjects with Chemotherapy Naïve Metastatic Melanoma | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2013-003398-91 | A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma | 2022-06-30 | bad-data |
| Reported results | 2013-003866-15 | MPACT EXTENSION STUDY: MULTICENTER, SURVIVAL DATA COLLECTION IN SUBJECTS PREVIOUSLY ENROLLED IN PROTOCOL CA046 | 2015-06-16 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-004054-21 | Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemo... | 2022-07-25 | bad-data |
| Reported results | 2014-000268-17 | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS ... | 2022-05-13 | due-trials |
| Listed as ongoing, but also has a completion date | 2014-001105-41 | A Phase 2, open-label, multicenter study to assess safety and efficacy of second/third-line treatment with nab-paclitaxel (ABI-007) in combination with epigenetic modifying therapy of CC-486, or immun... | 2023-08-17 | bad-data |
| Reported results | 2014-001408-23 | NAB-PACLITAXEL (ABRAXANE®) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE 2 STUDY (LAPACT) NAB-PACLITAXEL (ABRAXANE®)... | 2018-04-26 | due-trials |
| Reported results | 2014-001745-25 | A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastatic N... | 2017-04-20 | due-trials |
| Reported results | 2014-002108-25 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TR... | 2020-07-17 | due-trials |
| Reported results | 2014-002172-92 | A randomized, multicenter, open-label, Phase 2 study with a safety run-in part to evaluate safety, pharmacodynamics and efficacy of azacitidine compared to no anticancer treatment in children and youn... | 2019-10-08 | due-trials |
| Reported results | 2014-002320-27 | A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclero... | 2016-12-22 | due-trials |
| Reported results | 2014-002388-13 | A Phase 2, multicenter, open-label study to evaluate the pharmacokinetics, pharmacodynamics, safety and activity of azacitidine and to compare azacitidine to historical controls in pediatric subjects ... | 2019-05-24 | due-trials |
| Listed as ongoing, but also has a completion date | 2014-002675-29 | A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy and Safety of CC-486 (oral azacitidine) Alone and in Combination with Durvalumab (MEDI4736)... | 2023-09-14 | bad-data |
| Reported results | 2014-002981-64 | A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS | 2019-06-03 | due-trials |
| Exempt, with results | 2014-003056-31 | Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects with Chronic Lymphoc... | 2020-07-07 | not-yet-due |
| Reported results | 2014-003220-52 | A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Wo... | 2017-11-21 | due-trials |
| Reported results | 2014-003804-66 | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY TO EVALUATE NAB-PACLITAXEL (ABRAXANE®) AS MAINTENANCE TREATMENT AFTER INDUCTION WITH NAB-PACLITAXEL PLUS CARBOPLATIN IN SUBJ... | 2019-08-01 | due-trials |
| Ongoing | 2014-005614-29 | A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembrolizuma... | not-yet-due | |
| Reported results | 2015-000319-41 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis | 2020-06-17 | due-trials |
| Ongoing | 2015-000344-42 | A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia H... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2015-001600-64 | A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis | 2016-02-15 | bad-data |
| Completed, but no date, and reported results Terminated | 2015-001693-18 | A Phase 2, Open-Label Study to Explore the Pharmacodynamic and Clinical Effects of Mongersen (GED-0301) in Subjects with Active Crohn's Disease Studio di fase 2, in aperto per valutare gli effe... | bad-data | |
| Reported results | 2015-001924-40 | A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of adult and adolescent subjects with active... | 2017-10-19 | due-trials |
| Reported results | 2015-001925-18 | A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn?s disease. ... | 2018-01-22 | due-trials |
| Reported results | 2015-001963-37 | A Phase 3, long-term active treatment extension study of mongersen (GED-0301) in subjects with Crohn's disease Dlouhodobé následné klinické hodnocení fáze 3 s aktivní léčbou přípravkem Mongersen (G... | 2018-01-04 | due-trials |
| Reported results | 2015-002025-19 | A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Active... | 2019-11-28 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-002500-91 | A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis | 2023-01-05 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-003224-31 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Tr... | 2021-01-05 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-003225-33 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) versus Placebo in Adults with Non Transfusion Dependent Beta (... | 2022-11-28 | bad-data |
| Trial is partly outside EEC, and reported results | 2015-003314-24 | A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis | 2019-07-29 | bad-data |
| Reported results | 2015-003364-36 | A Phase 2, Open-label, Multicenter Study to Explore the Efficacy and Safety of Mongersen (GED-0301) in Subjects with Active Ulcerative Colitis. | 2017-08-08 | due-trials |
| Reported results | 2015-003454-41 | A Phase 3, Double-Blind, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Placebo For The Treatment Of Anemia Due To IPSS-R Very Low, Low, Or Intermediate Risk Myel... | 2020-11-26 | due-trials |
| Exempt, with results | 2015-003516-21 | A Phase 1/2, open label, multicenter study to assess the safety and tolerability of durvalumab (anti-PD-L1 antibody) as monotherapy and in combination therapy in subjects with lymphoma or chronic lymp... | 2022-08-21 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2015-003596-30 | A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Highe... | 2021-12-27 | bad-data |
| Exempt | 2015-003951-23 | A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus... | not-yet-due | |
| Exempt, with results | 2015-004831-11 | A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subject... | 2022-09-06 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2015-005173-20 | A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or wi... | 2022-04-24 | bad-data |
| Completed, but no date | 2016-000069-22 | A PHASE 2, OPEN-LABEL, SINGLE-ARM ROLLOVER STUDY TO EVALUATE LONG-TERM SAFETY IN SUBJECTS WHO PARTICIPATED IN OTHER CELGENE SPONSORED CC-486 (ORAL AZACITIDINE) CLINICAL TRIALS IN SOLID TUMORS AND HEMA... | bad-data | |
| Exempt | 2016-000860-40 | A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSE- ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF CC-220 AS MONOTHERAPY AND IN CO... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2016-001209-17 | A PHASE 2, MULTICENTER, OPEN-LABEL, STUDY TO DETERMINE THE SAFETY AND EFFICACY FOR THE COMBINATION OF DURVALUMAB (DURVA) AND DARATUMUMAB (DARA) (D2) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE M... | 2022-01-03 | bad-data |
| Reported results Terminated | 2016-001706-42 | A Phase 2, Open-Label, Multiple Cohort, Single-Arm, Multi-Center Trial To Determine The Safety, Feasibility, And Efficacy Of JCAR015 In Adult Subjects With B-Cell Acute Lymphoblastic Leukemia Ensay... | 2017-03-01 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-002903-25 | A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors. | 2023-09-14 | bad-data |
| Other | 2016-003473-17 | A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopath... | not-yet-due | |
| Reported results | 2016-003778-42 | A Phase 1/2 Open-label, Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor-Risk (IPI ≥ 3) Diffuse Large B-Cell Lymphoma | 2020-12-16 | due-trials |
| Reported results | 2016-003801-32 | Multicenter, Single-arm, Phase 2 Study to Determine the Efficacy for the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)... | 2017-12-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-004574-17 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | 2021-08-03 | bad-data |
| Listed as ongoing, but also has a completion date | 2017-000106-38 | A Phase 2, Single-arm, Multi-cohort, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma | 2023-12-15 | bad-data |
| Other | 2017-000322-35 | A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and Without... | not-yet-due | |
| Exempt | 2017-001236-19 | A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Mul... | not-yet-due | |
| Other | 2017-001465-24 | Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells Protocollo di follow-up a lungo termine per i soggetti trattati con cellule T modificate geneticamente | not-yet-due | |
| Trial is outside EEC | 2017-002146-72 | A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (REVLIMID®) in Pediatric Subjects from 1 to ≤ 18 Years of Age with Relapsed o... | bad-data | |
| Listed as ongoing, but also has a completion date | 2017-002245-29 | A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma | 2023-12-20 | bad-data |
| Ongoing | 2017-002290-19 | A Phase 3b randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refrac... | not-yet-due | |
| Other | 2017-003190-34 | A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Ris... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2017-004292-31 | Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease | 2023-09-18 | bad-data |
| Listed as ongoing, but also has a completion date | 2017-004293-33 | Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn¿s Disease Estudo de Ind... | 2023-11-21 | bad-data |
| Ongoing | 2017-004294-14 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn¿s Disease Estudo de fase 3, multicêntrico,... | not-yet-due | |
| Ongoing | 2017-004295-55 | A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease | not-yet-due | |
| Other | 2018-000264-28 | A Phase 2, Multi-Cohort, Open-Label, Multi-center Study to Evaluate the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk ... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2018-000929-32 | A global randomized multicenter Phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive ... | 2023-10-23 | bad-data |
| Ongoing | 2018-001023-38 | A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2018-001132-22 | A Phase 3, Randomized, Blinded, Placebo-controlled Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects with Locally Adva... | 2019-06-26 | bad-data |
| Listed as ongoing, but also has a completion date | 2018-001246-34 | A Phase 1b/2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory (r/r) B-cell acute lymphoblastic leuk... | 2024-01-26 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002608-15 | A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis | 2022-02-09 | bad-data |
| Listed as ongoing, but also has a completion date | 2018-002735-26 | A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH EARLY, OLIGOARTICULAR PSORIATIC ... | 2023-07-05 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002748-10 | A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects with Psoriatic Arthritis | 2022-05-11 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002850-58 | A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PS... | 2021-11-04 | bad-data |
| Other | 2018-002915-93 | A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials. | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-002918-12 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects from 6 through 17 Years of Age with Moderat... | 2023-03-27 | bad-data |
| Exempt | 2018-003235-29 | A PHASE I/II, MULTI-CENTER, OPENLABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF AN ORALLY AVAILABLE SMALL MOLECULE, CC-99282, ALONE AND IN COMBINATION WITH ANTILYMPHOMA... | not-yet-due | |
| Ongoing | 2018-003411-21 | A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary mye... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004431-79 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSEFINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVER F... | 2021-09-28 | bad-data |
| Exempt | 2018-004767-31 | A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subje... | not-yet-due | |
| Other | 2019-000208-13 | A phase 2a study to evaluate the safety and pharmacokinetics of Luspatercept (ACE-536) in paediatric Participants who require regular red blood cell transfusions due to beta (β) thalassemia | not-yet-due | |
| Other | 2019-003497-13 | A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis | not-yet-due | |
| Other | 2019-004081-18 | A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL... | not-yet-due | |
| Ongoing, reported early | 2019-004108-37 | A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-004194-95 | A Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with advanced cancers. | 2024-02-19 | bad-data |
| Exempt | 2020-000354-10 | A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO ASSESS SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF CC-220, ALONE AND IN COMBINATION WITH AN ANTI-CD20 MONOCLONAL ANTIBODY (MAB) IN SUBJECTS WITH... | not-yet-due | |
| Ongoing | 2020-000431-49 | A Phase 3, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or R... | not-yet-due | |
| Other | 2020-000607-36 | A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOMITA... | not-yet-due | |
| Exempt | 2020-003248-10 | An exploratory phase 1/2 trial to determine recommended phase 2 dose (RP2D), safety and preliminary efficacy of bb2121 (ide-cel) combinations in subjects with refractory/relapsed multiple myeloma E... | not-yet-due | |
| Other | 2020-004335-24 | A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS | not-yet-due | |
| Ongoing | 2020-004336-16 | A Phase 3, Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects w... | not-yet-due | |
| Reported results | 2020-005212-22 | A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects with Moderate to Sever... | 2022-11-09 | due-trials |
| Ongoing | 2021-001957-30 | A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib And Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) In Subjects With Relaps... | not-yet-due | |
| Other | 2021-002308-11 | A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (RPC1063) in pediatric subjects with moderately to sev... | not-yet-due | |
| Other | 2021-004928-15 | A Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) for the Treatment of Anemia in Adults with Alpha (a... | not-yet-due | |
| Other | 2021-005019-30 | A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately to... | not-yet-due | |
| Exempt | 2021-005167-51 | An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel T... | not-yet-due |